Denosumab, alendronate and zoledronate failure to suppress bone resorption markers in a woman affected by severe osteoporosis and subclinical hypercortisolism due to an adrenal adenoma: A case report

AbstractIn this study, we aim to clarify the influence based on bone resorption markers at onset of stress fracture. Also, we will clarify the state of the bone resorption markers of female long distance runners who have a history of stress fracture and also ones who routinely practices running long distances. Participants comprised 19 female long distance athletes. The survey period was 2011–2014, and we measured u-NTX as a bone resorption marker at least twice a year, taking the mean±SD of the periodic measured values without stress fracture as the mean value. Measurements were collected sample when stress fractures developed. 132 u-NTX measurements were taken from 19 participants. As a result, the average was 41.03±12.31 nmolBCE/mmolCRE (Q1: 33.15, Q2: 40.55, Q3: 47.95). In six of the 19 participants, u-NTX could be measured following a stress fracture. The mean value of u-NTX for those participants was 40.16±9.10 nmolBCE/mmolCRE, increasing to 64.08±16.07 nmolBCE/mmol CRE with the stress fracture (p<0.01). The findings showed that, in adult female long distance runners, u-NTX values when there was no stress fracture were within the standard value for mean premenopausal women, but increased when the athletes suffered from a stress fracture.

Download Full-text

Bar Attachement Retained Mandibular Complete Denture: A Case Report

Integrative Journal of Medical Sciences ◽

10.15342/ijms.7.235 ◽

2020 ◽

Vol 7 ◽

Author(s):

Afafe Taouili ◽

Yasmina Cheikh ◽

Samira Bellemkhannate

Keyword(s):

Case Report ◽

Bone Resorption ◽

Clinical Case ◽

Complete Denture ◽

Bearing Surface ◽

Mandibular Arch ◽

Physiological Conditions ◽

Laboratory Techniques ◽

Mandibular Complete Denture

The mandibular complete denture is a challenge for the dentist. Unfavorable anatomical and physiological conditions such low bearing surface and a significant bone resorption, often compromise the prosthetic retention.The exploitation of root stumps is a reliable alternative that leads to a better prosthetic integration by increasing the retention, if the total prosthesis is connected to these root stumps via axial ball or bar attachments.In addition, this prosthetic alternative considerably improves the patient's comfort and masticatory coefficient and favors the preservation of the bone capital, provided that the requirements of root preservation as well as clinical and laboratory techniques are respected.We would like to illustrate this by presenting a clinical case in which we used the connecting bar in the mandibular arch.

Download Full-text

Intravascular Papillary Endothelial Tumor of the Adrenal Gland: A Case Report and Review of Literature

Advances in Nutrition & Food Science ◽

10.33140/anfs.04.03.01 ◽

2019 ◽

Vol 4 (3) ◽

Keyword(s):

Case Report ◽

Adrenal Gland ◽

Blood Clot ◽

Adrenal Adenoma ◽

Vascular Tumor ◽

Review Of Literature ◽

Intravascular Papillary Endothelial Hyperplasia ◽

Papillary Endothelial Hyperplasia ◽

Malignant Lesions ◽

Head Neck

Intravascular Papillary Endothelial Hyperplasia (IPEH) or Masson’s Tumor is a benign vascular tumor, most commonly seen on the skin and usually on the head, neck or extremities. It is more common in women with no age predilection. Visceral involvement is very rare, with about 30 intra-abdominal reports. We present a case report of a 58 year old woman who underwent a CT scan due to dysphagia complaints, with an incidental known finding of growth in the adrenal adenoma, which was 5 cm in diameter on hospitalization. The patient underwent laparoscopic adrenalectomy. Biopsy results demonstrated a brownish yellow lesion, 2.8 cm in diameter, composed of a blood clot and septate. Immunochemical staining for CD31 and CD34 was positive and the lesion was diagnosed as an IPEH of pure form. Our review of literature examines different forms of IPEH, previous reports and characteristics of Masson’s tumors in the adrenal gland and stratifies ways of differentiation it from other benign or malignant lesions of the adrenal.

Download Full-text

Gastrectomy induces negative changes of bone resorption markers and volumetric bone mineral density (VBMD) of lumbar spine in one-year study

Bone ◽

10.1016/j.bone.2012.02.452 ◽

2012 ◽

Vol 50 ◽

pp. S145-S146

Author(s):

W. Krupski⁎ ◽

M.R. Tatara ◽

A. Dabrowski ◽

P. Bury ◽

G. Wallner

Keyword(s):

Bone Mineral Density ◽

Lumbar Spine ◽

Bone Resorption ◽

Bone Mineral ◽

Volumetric Bone Mineral Density ◽

Mineral Density ◽

Bone Resorption Markers ◽

One Year

Download Full-text

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2018-214729 ◽

2019 ◽

Vol 78 (6) ◽

pp. 754-760 ◽

Cited By ~ 14

Author(s):

Sudha Visvanathan ◽

Stefan Daniluk ◽

Rafał Ptaszyński ◽

Ulf Müller-Ladner ◽

Meera Ramanujam ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Bone Resorption ◽

Primary Endpoint ◽

Study Drug ◽

Nuclear Factor Κb ◽

Inadequate Response ◽

Serious Adverse Events ◽

Double Blind ◽

Autoantibody Production ◽

Bone Resorption Markers

ObjectiveTo evaluate the safety, efficacy and therapeutic mechanism of BI 655064, an antagonistic anti-CD40 monoclonal antibody, in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX-IR).MethodsIn total, 67 patients were randomised to receive weekly subcutaneous doses of 120 mg BI 655064 (n=44) or placebo (n=23) for 12 weeks. The primary endpoint was the proportion of patients who achieved 20% improvement in American College of Rheumatology criteria (ACR20) at week 12. Safety was assessed in patients who received at least one dose of study drug.ResultsAt week 12, the primary endpoint was not met, with 68.2% of patients treated with BI 655064 achieving an ACR20 vs 45.5% with placebo (p=0.064); using Bayesian analysis, the posterior probability of seeing a difference greater than 35% was 42.9%. BI 655064 was associated with greater changes in CD40–CD40L pathway-related markers, including reductions in inflammatory and bone resorption markers (interleukin-6, matrix metalloproteinase-3, receptor activator of nuclear factor-κB ligand), concentration of autoantibodies (immunoglobulin [Ig]G rheumatoid factor [RF], IgM RF, IgA RF) and CD95+ activated B-cell subsets. No serious adverse events (AEs) related to BI 655064 treatment or thromboembolic events occurred; reported AEs were mainly of mild intensity.ConclusionAlthough blockade of the CD40–CD40L pathway with BI 655064 in MTX-IR patients with RA resulted in marked changes in clinical and biological parameters, including reductions in activated B-cells, autoantibody production and inflammatory and bone resorption markers, with a favourable safety profile, clinical efficacy was not demonstrated in this small phase IIa study.Trial registration numberNCT01751776

Download Full-text